Integra LifeSciences (IART) director awarded 17,700 deferred RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SCHADE CHRISTIAN S reported acquisition or exercise transactions in this Form 4 filing.

INTEGRA LIFESCIENCES HOLDINGS CORP director Christian S. Schade received a grant of 17,700 restricted stock units (RSUs) tied to the company’s common stock. The award was made at no cash cost under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan.

The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Schade elected to defer delivery of the underlying shares until a lump-sum payment is made in the calendar year after his service on the Board ends, or a later year he elected. Following this grant, he holds 17,700 RSUs directly from this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHADE CHRISTIAN S

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	17,700	$0.00	--

Holdings After Transaction: Restricted Stock Units — 17,700 shares (Direct, null)

Footnotes (1)

Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of IART common stock. RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. The reporting person elected to defer receipt of the shares underlying the RSUs. In accordance with his deferral election, vested shares will be delivered to the reporting person in one lump sum, in the calendar year next following the calendar year in which the reporting person's termination of service on the Board of Directors occurs (unless the reporting person elected a later calendar year).

Key Figures

RSUs granted: 17,700 units Transaction price per RSU: $0.0000 per unit Underlying common shares: 17,700 shares +2 more

5 metrics

RSUs granted 17,700 units Restricted stock units awarded to director on May 7, 2026 vesting schedule

Transaction price per RSU $0.0000 per unit Indicates compensation grant, not open-market purchase

Underlying common shares 17,700 shares Each RSU represents one share of IART common stock

RSUs after transaction 17,700 units Total restricted stock units held from this award following grant

Vesting date May 7, 2026 RSUs vest in full on one-year anniversary of grant date

Key Terms

Restricted Stock Units, Equity Incentive Plan, deferral election, vest, +1 more

5 terms

Restricted Stock Units financial

"Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

deferral election financial

"The reporting person elected to defer receipt of the shares underlying the RSUs."

vest financial

"RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

termination of service financial

"in the calendar year next following the calendar year in which the reporting person's termination of service on the Board of Directors occurs"

Form 4 Insider Transactions: What Each Field Means →

05/11/2026 - 04:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHADE CHRISTIAN S

(Last)

(First)

(Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON

NEW JERSEY

08540

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/07/2026		A		17,700		⁽²⁾	⁽²⁾	Common Stock	17,700	$0	17,700	D

Explanation of Responses:

1. Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of IART common stock.

2. RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. The reporting person elected to defer receipt of the shares underlying the RSUs. In accordance with his deferral election, vested shares will be delivered to the reporting person in one lump sum, in the calendar year next following the calendar year in which the reporting person's termination of service on the Board of Directors occurs (unless the reporting person elected a later calendar year).

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Christian S. Schade	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did INTEGRA LIFESCIENCES (IART) disclose about Christian S. Schade in this Form 4?

INTEGRA LIFESCIENCES reported that director Christian S. Schade received 17,700 restricted stock units. The RSUs were granted under the company’s equity incentive plan and give him a contingent right to receive the same number of IART common shares upon settlement.

How many restricted stock units did Christian S. Schade receive from INTEGRA LIFESCIENCES (IART)?

Christian S. Schade received 17,700 restricted stock units. Each RSU represents a contingent right to receive one share of IART common stock, so the award corresponds to 17,700 underlying common shares if and when the units settle in stock.

When do Christian S. Schade’s IART restricted stock units vest and become earned?

The 17,700 restricted stock units vest in full on the one-year anniversary of the grant date of May 7, 2026. Vesting means the award becomes earned, subject to the other terms and conditions of INTEGRA LIFESCIENCES’ equity incentive plan.

Under which plan were the new IART restricted stock units for Christian S. Schade granted?

The RSUs were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. This plan governs the terms of equity awards, including how and when restricted stock units vest and settle into common shares.

Did Christian S. Schade pay cash for the 17,700 IART restricted stock units?

No cash price was reported for the 17,700 restricted stock units; the transaction price per unit is shown as 0.0000. This indicates a compensation-related equity grant rather than an open-market purchase of INTEGRA LIFESCIENCES common stock.

When will Christian S. Schade actually receive IART shares from these restricted stock units?

Schade elected to defer receipt of the shares underlying the RSUs. According to the disclosure, vested shares will be delivered in one lump sum during the calendar year after his Board service ends, unless he chose an even later calendar year.